Mumbai: A study conducted by Tata Memorial Hospital in Mumbai has shown that adding Nimotuzumabto the standard treatment regimen significantly improves the 10-year overall survival rate for patients with locally advanced squamous cell carcinoma of the head and neck. Patients with head and neck cancer who received Nimotuzumab in combination with concurrent radiotherapy and cisplatin had a 10-year overall survival …
